Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,140.77
(
0.07%
)
US TECH 100
26,412.00
(
-0.19%
)
Dow Jones
49,251.10
(
0.80%
)
Brent Oil
109.53
(
-2.53%
)
Bitcoin
76,228.20
(
0.60%
)
News Focus
News Focus
Post# of 257470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122909
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 232319

Monday, 06/22/2020 10:19:19 AM

Monday, June 22, 2020 10:19:19 AM

Post# of 257470
ALT starting phase-2 trial of HepTcell for HBV:

https://www.globenewswire.com/news-release/2020/06/22/2051121/0/en/Altimmune-Announces-IND-Clearance-for-a-Phase-2-Trial-of-HepTcell-Immunotherapeutic-for-the-Treatment-of-Chronic-Hepatitis-B.html

HepTcell is an immunotherapeutic product candidate composed of nine synthetic HBV-derived peptides formulated with IC31, a TLR9-based adjuvant from Valneva SE. The HBV peptides were designed to drive T cell responses against all HBV genotypes in patients of diverse genetic background.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today